DoorDash Makes Proposal to Buy Deliveroo for $2.40 a Share
Deliveroo Plc. said it received a proposal from rival delivery company DoorDash Inc. to buy the UK-based startup for £1.80 ($2.40) a share.
Deliveroo said it would be 'minded to recommend such an offer' to shareholders, should a firm offer be made at those terms. Based on Deliveroo's shares outstanding, the offer may value the company at about £2.7 billion, according to calculations by Bloomberg.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Aston Martin reveals track-day version of Valkyrie Le Mans Hypercar
Aston Martin is billing a new track-day version of its Valkyrie Le Mans Hypercar as near-identical to the race car. The Aston Martin Valkyrie LM Hypercar boasts the same maximum power output of 520kW (697bhp) from its 6.5-litre V12 as the World Endurance Championship and IMSA Sportscar Championship contender. Advertisement The differences between the two cars represent, said Aston head of endurance motorsport Adam Carter, 'only a few minor deviations to ensure it is a non-homologated variant and is accessible for customers to experience and enjoy'. Aston Martin Valkyrie track day car Aston Martin Valkyrie track day car Aston Martin Aston Martin This will include the removal of FIA-regulation electronics, a bespoke cockpit interface tailored for track days and the use of Pirelli rather than Michelin tyres. 'Valkyrie LM represents the most authentic Hypercar track experience that is now available,' he continued. Aston CEO Adrian Hallmark said: 'With Valkyrie LM, there has never been an opportunity to get closer to the raw dynamic forces and state-of-the-art technology deployed by the Hypercar currently competing in WEC and IMSA. Advertisement 'Valkyrie LM is an exquisite opportunity to be part of the most exclusive Aston Martin owners' club in the world, a group who can immerse themselves in the purest and most comparable endurance driving experience, one that would otherwise only be available to our works drivers operating at the very limit of sportscar racing's highest echelon.' The ownership experience Aston Martin Valkyrie track day car Aston Martin Valkyrie track day car Aston Martin Aston Martin Production of the Valkyrie LM will be limited to 10 cars, whose owners will be able to take part in a special programme during Aston's so-called 'Unleashed' track experience events. Deliveries of the first Valkyrie LMs will start in the middle of 2026 ahead of two track days at Aston Unleashed' events later in the year. Aston has put the price of the Valkyrie LM at 'circa $5 million Usd. plus taxes'. Advertisement Aston Martin will look after the cars and offer a driver development programme tailored, it explained, 'to support harness and optimise their driving ability and provide them with the ultimate top-flight motorsport experience'. The British manufacturer is taking a leaf out of Ferrari's book after the launch of the Modificata version of its two-time Le Mans-winning 499P LMH. Ferrari is understood to have sold well in excess of 20 Modificatas, which take part in its Clienti events, since its launch at the end of 2023. The Ferrari, however, is different in key areas to the LMH – one of these a push-to-pass power boost from its hybrid system, which increases peak power to 640kW or 860bhp. Aston Martin Valkyrie track day car Aston Martin Valkyrie track day car Aston Martin Aston Martin Advertisement Deliveries of the first Valkyrie LMs will start in the middle of next year ahead of two track days at Formula 1-grade circuits later in the year. Plans to race the Valkyrie in the WEC were announced in 2019 before being put on hold early the following year, but development of the still-born LMH fed into the AMR Pro track day car. This car was the starting point for the development of the LMH that entered competition this year. To read more articles visit our website.
Yahoo
38 minutes ago
- Yahoo
Two-fifths of consumers halt online purchase over no free delivery or return
More than two-fifths of consumers have stopped an online purchase because the retailer does not offer free delivery or return, a survey suggests. While 42% consider having to pay for delivery or return a deal-breaker, 13% also admit to buying multiple items with the plan to keep only one they like the most or that fits properly, the poll for KPMG found. KPMG said the findings highlighted the importance of free delivery and free returns to online shoppers but also the challenge posed to retailers from overuse of such schemes. In recent years, serial returners have placed pressure on the cost of returns for some retailers, and even led to resulting changes in postage policies. KPMG found that 13% of people say that when buying clothes or footwear online, they generally buy multiple sizes in order to find what fits best and then return the rest. Some 12% reported generally buying multiple items in one order to see which products they like the most and then returning the rest, with this practice rising to a quarter of those aged 18 to 24. Further, 6% said they buy an item to use or wear and then return 'as new' once finished with it. The survey also found that 14% of consumers said having no drop-off option or returns locker close to their home stopped them from making an online purchase – rising to a quarter of those aged 18 to 24. Linda Ellett, head of consumer, retail and leisure for KPMG UK, said: 'Free delivery or free and convenient returns options remain a key purchasing driver for many consumers shopping online. 'Companies are having to weigh these consumer demands up against the cost of such schemes, including due to a cohort of consumers that are repeat buying with no intention to keep all items – something that is clear in our research. 'Savvy retailers are increasingly utilising purchasing data to categorise customers into those making genuine returns choices versus the unprofitable serial returner cohort. 'And as technology, including AI, evolves further, the ability to target those taking advantage of free returns policies will improve. This will help retailers reduce the risk of losing those who could become a lifetime shopper and are just gradually becoming accustomed to the brand's sizing and fit.' One Poll surveyed 3,000 UK consumers online between March 5-11.
Yahoo
an hour ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
